Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Invivyd's Pemgarda sales reach $15.4m as next-generation antibody readout slips after FDA talks

The COVID-19 antibody maker posted $15.4m in Pemgarda sales and $126.4m in cash, but the timing of its lead pipeline readout has changed.

16 Nov 2026 · Invivyd, Inc. IVVD · Company news

Invivyd booked $15.4m in net sales of Pemgarda (pemivibart), its COVID-19 antibody, for the three months to the end of September, the company said in its results on 16 November. Its own announcement described that figure as an 18% increase. The material available to CompePharma does not say which period that growth is measured against.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Invivyd, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →